Hello! You're looking at a policy document report on Overton

We track government policy, guidelines, think tank research, working papers and more to help our customers see the impact and influence of their work. Are you interested in seeing what information we have to offer? Request a free trial to our platform.

If you fund, produce or manage research or work to influence policy, we'd love to talk. Learn more on our homepage.

Long-acting ß2-agonists (LABA) plus Corticosteroids versus LABA Alone for Chronic Obstructive Pulmonary Disease

Canadian Agency for Drugs and Technologies in Health on March 27th 2007

See the 3 policy documents that cite this document

See report on the 3 policy documents that cite this document

See the 22 articles cited by this document

See report on the 22 articles cited by this document

Topics in this document

Health sciences Medicine Drugs Health Antiasthmatic drugs Pulmonological procedures Pulmonology Medical treatments Medical specialties Pharmacology Clinical medicine Salmeterol Beta2-adrenergic agonist Bronchodilator Formoterol Long-acting beta-adrenoceptor agonist Obstructive lung disease Spirometry Chronic obstructive pulmonary disease Medical research Bronchodilators Budesonide/formoterol Randomized controlled trial Budesonide Shortness of breath Health care Quality-adjusted life year Incremental cost-effectiveness ratio Chronic condition Asthma

Related SDGs

SDG 3: Good Health and Well-being

Cites research funded by

1 Health Technology Assessment programme 1 Health Technology Assessment Programme 1 National Institute for Health Research

Citations

Cited by 3 other policy documents (all of them are from other policy sources)

This document is made up of multiple PDFs

The references found in each have been combined below. If an item has been cited in more than one PDF then it'll appear more than once, linked to the relevant PDF and page number.

Recognized names mentioned in this document

Overton only tracks names from certain institutions. Names must have been cited in at least one policy document and their corresponding affiliation has to be found nearby - you can find more details on the help page.

Andrew McIvor at McMaster University

On page 4 of Long-acting ß2-agonists (LABA) plus Corticosteroids versus LABA Alone for Chronic Obstructive Pulmonary Disease (or quick view this section)